Edition:
India

STADA Arzneimittel AG (STAGn.DE)

STAGn.DE on Xetra

81.78EUR
16 Nov 2018
Change (% chg)

€-0.92 (-1.11%)
Prev Close
€82.70
Open
€82.50
Day's High
€82.54
Day's Low
€81.32
Volume
29,120
Avg. Vol
36,017
52-wk High
€90.24
52-wk Low
€78.40

Latest Key Developments (Source: Significant Developments)

Nidda Healthcare: Bain Capital Private Equity And Cinven Partners Announce Public Delisting Tender Offer For Remaining STADA Shares
Monday, 1 Oct 2018 

Oct 1 (Reuters) - NIDDA HEALTHCARE GMBH::NIDDA HEALTHCARE - BAIN CAPITAL PRIVATE EQUITY AND CINVEN PARTNERS ANNOUNCE PUBLIC DELISTING TENDER OFFER FOR REMAINING STADA SHARES.  Full Article

Nidda Healthcare GmbH Bids For STADA
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Nidda Healthcare GmbH::NIDDA HEALTHCARE GMBH BIDS FOR STADA.FOLLOWING ANNOUNCEMENT, NIDDA WILL INSTRUCT STADA UNDER EXISTING DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT.  Full Article

STADA Arzneimittel: Peter Goldschmidt To Succeed Claudio Albrecht As CEO
Monday, 3 Sep 2018 

Sept 3 (Reuters) - STADA ARZNEIMITTEL AG ::PETER GOLDSCHMIDT TO SUCCEED CLAUDIO ALBRECHT AS STADA'S CEO.WITH EFFECT FROM SEPTEMBER 1, 2018.SAYS ALBRECHT WILL NOT BE TAKING A SEAT ON STADA GROUP'S SUPERVISORY BOARD.  Full Article

STADA H1 Adjusted Net Income Up 31 Pct At EUR 149.7 Million
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - STADA Arzneimittel AG ::REPORTED GROUP SALES DECREASED BY 1 PERCENT IN FIRST SIX MONTHS OF 2018 TO EUR1,137.5 MILLION.H1 REPORTED EBITDA INCREASED BY 18 PERCENT TO EUR260.6 MILLION.H1 ADJUSTED EBITDA ROSE BY 10 PERCENT TO EUR 261.7 MILLION.H1 ADJUSTED NET INCOME INCREASED BY 31 PERCENT TO EUR 149.7 MILLION.  Full Article

STADA Arzneimittel Becomes Majority Shareholder Of Bioceuticals Arzneimittel AG
Monday, 6 Aug 2018 

Aug 6 (Reuters) - STADA ARZNEIMITTEL AG ::BECOMES MAJORITY SHAREHOLDER OF BIOCEUTICALS ARZNEIMITTEL AG.NOW HAS A 51.34 PERCENT STAKE IN BIOCEUTICALS ARZNEIMITTEL AG.PARTIES AGREED TO MAINTAIN CONFIDENTIALITY WITH REGARD TO FINANCIAL CONDITIONS OF TRANSACTION.  Full Article

STADA: Results Of Tender Offer Regarding STADA-Bond 2015/2022
Wednesday, 11 Jul 2018 

July 11 (Reuters) - STADA ARZNEIMITTEL AG ::SAYS HOLDERS VALIDLY TENDERED NOTES IN AN AGGREGATE PRINCIPAL AMOUNT OF EUR 15,656,000 FOR REPURCHASE DURING TENDER PERIOD.PAYMENT DATE IS EXPECTED TO BE 16 JULY 2018..AFTER PAYMENT DATE NOTES WILL STILL BE OUTSTANDING IN AGGREGATE AMOUNT OF EUR 274,070,000.  Full Article

STADA Says Miguel Pagan To Become Head of Production
Monday, 16 Apr 2018 

April 16 (Reuters) - STADA Arzneimittel AG ::SAYS MIGUEL PAGAN TO BECOME EXECUTIVE BOARD MEMBER FOR PRODUCTION AND DEVELOPMENT.SAYS STEFFEN WAGNER TO BE HEAD OF EUROPE, CARSTEN CRON TO HEAD EMERGING MARKETS.SAYS ROBERT KNERR TO FOLLOW WOLTER KUIZINGA AS HEAD OF BUSINESS DEVELOPMENT.  Full Article

Stada Says Domination And Profit And Loss Transfer Agreement Concluded
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Stada ::DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT PURSUANT TO SECTIONS 291 ET SEQQ. AKTG CONCLUDED BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH.DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT STILL REQUIRES CONSENT OF EXTRAORDINARY GENERAL MEETING OF STADA, WHICH IS PLANNED FOR 2 FEBRUARY 2018.SHAREHOLDERS' MEETING OF NIDDA HEALTHCARE HAS ALREADY CONSENTED TO AGREEMENT ON TODAY'S DATE.NIDDA HEALTHCARE IS OFFERING TO ACQUIRE SHARES OF OUTSIDE STADA SHAREHOLDERS IN RETURN FOR CASH COMPENSATION OF EUR 74.40 PER SHARE.DOMINATION AGREEMENT PROVIDES FOR ANNUAL RECURRING COMPENSATION PAYMENT FOR OUTSIDE SHAREHOLDERS OF EUR 3.82 GROSS PER SHARE.  Full Article

Stada confident domination agreement can be struck in Q1 2018
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Stada :CEO say can confirm medium-term targets.CEO says are confident that a profit and domination agreement with Elliott can be concluded at an EGM in Q1 2018.  Full Article

Stada ‍says is on track to achieve targets for 2017
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Stada Arzneimittel AG says :Stada shows good business development in the third quarter of 2017 and the first nine months.9M sales 1.698 billion eur.‍Well on track to achieve targets for 2017​.Q3 reported group sales ‍554.8​ million eur.‍Q3 adjusted ebitda 109.8​ million eur.‍Q3 adjusted net income 31.2​ million eur.‍Expects key earnings figures in q4 of 2017 to be lower than corresponding figures in q3 of 2017​.‍2017 group sales adjusted for currency and portfolio effects are expected to be in range of euro 2.280 billion to euro 2.350 billio​.‍Sees 2017 adjusted ebitda between euro 430 million and euro 450 million​.‍Sees 2017 adjusted net income between euro 195 million and euro 205 million​.  Full Article